RBBP9 Monoclonal antibody

RBBP9 Monoclonal Antibody for WB, IF, IHC, ELISA

Host / Isotype

Mouse / IgG2b

Reactivity

human

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

CloneNo.

1H6D8

Cat no : 66015-1-Ig

Synonyms

RBBP9



Tested Applications

Positive WB detected inA549 cells
Positive IHC detected inhuman pancreas cancer tissue, human pancreas tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHela cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

The immunogen of 66015-1-Ig is RBBP9 Fusion Protein expressed in E. coli.

Tested Reactivity human
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen RBBP9 fusion protein Ag17864
Full Name retinoblastoma binding protein 9
Calculated Molecular Weight 186 aa, 21 kDa
Observed Molecular Weight 22 kDa
GenBank Accession NumberBC015938
Gene Symbol RBBP9
Gene ID (NCBI) 10741
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

RBBP9, also named as BOG, RBBP10, RBBP-9, RBBP-10 and Protein BOG, belongs to the RBBP9 family. It may play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-β1 through interaction with retinoblastoma and the subsequent displacement of E2F-1. RBBP9 is a tumor-associated serine hydrolase activity required for pancreatic neoplasia. It mediates suppression of TGF-β signaling is required for E-cadherin expression as loss of the serine hydrolase activity leads to a reduction in E-cadherin levels and a concomitant decrease in the integrity of tumor cell–cell junctions..RBBP9 protein levels were equivalent in paired primary tumor and nonneoplastic specimens(PMID:20080647)

Protocols

Product Specific Protocols
WB protocol for RBBP9 antibody 66015-1-IgDownload protocol
IHC protocol for RBBP9 antibody 66015-1-IgDownload protocol
IF protocol for RBBP9 antibody 66015-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols